An innovative platform and smartphone app to deliver tailored interventions and facilitate completed referrals related to substance use.

一个创新的平台和智能手机应用程序，可提供量身定制的干预措施并促进完成与药物使用相关的转介。

• 批准号: 9896540
• 负责人: Hans Morefield
• 金额: $ 18.47万
• 依托单位: CHESS MOBILE HEALTH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9896540
• 关键词: Accident and Emergency department; Address; Adherence; Alcohol consumption; Alcohol or Other Drugs use; Behavior Therapy; Caring; Cellular Phone; Clinical; Computers; Data; Destinations; Disease; Drug usage; Elements; Funding; Goals; Health; Health Personnel; Individual; Intervention; Knowledge; Mind; Modification; Monitor; National Institute of Drug Abuse; Participant; Patient Care; Patient Noncompliance; Patients; Pharmaceutical Preparations; Phase; Primary Health Care; Provider; Randomized; Randomized Clinical Trials; Recommendation; Recovery; Research; Risk; Screening Result; Screening procedure; Secure; Self Management; Small Business Innovation Research Grant; Substance Use Disorder; Substance abuse problem; Technology; Testing; Validation; Work; base; care providers; compliance behavior; design; digital; efficacy study; efficacy testing; follow-up; health information technology; improved; innovation; medical specialties; outreach; patient engagement; personalized intervention; primary care setting; programs; prototype; reduced substance use; response; satisfaction; screening, brief intervention, referral, and treatment; smartphone Application; substance abuse treatment; success; tool; trend; usability; willingness

Abstract The goal of this fast-track SBIR proposal is to increase patient adherence to SBIRT-related recommendations given to patients by a primary care provider (PCP). The success of SBIRT (Screening, Brief Intervention, and Referral to Treatment) in the primary care setting has been inconsistent in terms of patients following through on treatment referral recommendations, with averages as low as 10%. For a variety of reasons, many patients, irrespective of their specific disease, do not adhere well to clinical recommendations. One way to improve adherence has been to personalize the recommendations for each individual’s needs, especially using digital technology, such as apps. The aim of NIDA to develop a sophisticated smart phone based tool for improving patient follow up to SBIRT recommendations is therefore well justified. CHESS Health has already developed an automated digital tool (eIntervention) with key elements requested by this RFA. eIntervention is designed to encourage patient adherence to PCP recommendations following SBIRT. Using a variety of the RFA required functionalities, eIntervention is designed to facilitate and motivate each patient to enter treatment, once that patient has been identified by SBIRT as having a substance use disorder (SUD) or as being at risk of such. eIntervention is commercially available and was developed in response to customer requests. However, eIntervention does not contain all of the functionalities requested by NIDA in this RFA and we do not have data to validate efficacy. Such validation is important for supporting wide spread dissemination. We propose to enhance our existing eIntervention solution with new functionalities that address the requirements set forth in this RFA and carry out a randomized study of efficacy. In Phase I, our Specific Aim is to evaluate feasibility of our program for improving adherence to SBIRT recommendations to patients from PCPs. This Specific Aim will be accomplished in two Tasks: Task 1: Add functionality to our prototype that address most requirements outlined in the RFA. Task 2: Demonstrate acceptability, feasibility, and preliminary efficacy of the prototype eIntervention in improving patient linkage to and engagement in indicated follow-up specialty SUD care. If shown to be feasible, in Phase II, our Specific Aim is to evaluate a near commercial quality product that contains all of the features required by the RFA. The Specific Aim will be accomplished in two Tasks: Task 1: Modifications to the program (months 1-3). Task 2: The randomized clinical trial to test efficacy of SBIRT/eIntervention compared to SBIRT/TAU. Criteria for Success: We aim to double the current rate of follow-up specialty SUD care (e.g. go from ~17% to an achieved rate of ~35%), a highly impactful effect. All patients, including those identified as at risk, must show a reduction in substance use. Patients and PCPs must rank the program with an average of 3.5 on a five-point Likert scale for usability, satisfaction, and willingness to use with the program again.

抽象的 此快速 SBIR 提案的目标是提高患者对 SBIRT 相关建议的依从性 由初级保健提供者 (PCP) 向患者提供 SBIRT 的成功（筛查、简短干预和 初级保健机构中的转诊治疗）在患者后续治疗方面一直不一致 治疗转诊建议的平均比例低至 10% 由于多种原因，许多患者 无论其具体疾病如何，都没有很好地遵守临床建议是改善的一种方法。 坚持根据每个人的需求提供个性化的建议，尤其是使用数字化的 NIDA 的目标是开发一种基于智能手机的复杂工具来改进。 因此，患者遵循 SBIRT 建议进行随访是合理的。 CHESS Health 已经开发了一种自动化数字工具（eIntervention），其中包含所要求的关键要素 本 RFA 旨在鼓励患者遵守 PCP 的建议。 SBIRT。使用各种 RFA 所需的功能，电子干预旨在促进和激励 一旦 SBIRT 确定患者有物质使用行为，每位患者即可进入治疗 疾病（SUD）或有此类风险的电子干预是可商业获得的，并且是在 2017 年开发的。 然而，eIntervention 并不包含客户请求的所有功能。 NIDA 在本次 RFA 中没有数据来验证功效，这种验证对于支持广泛的治疗非常重要。 我们建议通过新功能来增强我们现有的电子干预解决方案。 满足本 RFA 中规定的要求并进行功效随机研究。 在第一阶段，我们的具体目标是评估我们提高 SBIRT 依从性的计划的可行性 PCP 向患者提出的建议将通过两项任务来实现： 任务 1：向我们的原型添加满足 RFA 中概述的大多数要求的功能。 任务 2：展示电子干预原型的可接受性、可行性和初步功效 改善患者与指定后续专业 SUD 护理的联系和参与。 如果被证明是可行的，在第二阶段，我们的具体目标是评估一种接近商业质量的产品， 包含 RFA 所需的所有功能 具体目标将通过两项任务来实现： 任务 1：修改计划（第 1-3 个月）。 任务 2：随机临床试验，测试 SBIRT/eIntervention 与 SBIRT/TAU 相比的功效。 成功标准：我们的目标是将目前的后续专业 SUD 护理率提高一倍（例如从约 17% 提高到 达到的比率约为 35%），这是一种非常有影响力的效果，所有患者，包括那些被确定为处于危险中的患者，都必须这样做。 显示物质使用减少。患者和 PCP 必须对该计划进行平均 3.5 分的评分。 可用性、满意度和再次使用该程序的意愿的五点李克特量表。